Have an eye on: VYNE Therapeutics Inc. (NASDAQ:VYNE) declared $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

The USA listed company saw a recent price trade of $2.64 and 86,973,600 shares have traded hands in the session. There are 3.05M shares which are traded as an average over the last three months period.  VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), today announced that it has entered into definitive agreements with institutional and accredited investors for the sale of an aggregate of 21,097,046 shares of its common stock at a purchase price of $2.37 per share in a registered direct offering priced at-the-market under Nasdaq Rules. The offering is expected to close on or about January 28, 2021, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds of the offering are expected to be approximately $50.0 million, prior to deducting placement agent’s fees and other offering expenses payable by VYNE. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

On 01-26-2k21 (Tuesday) Shareholders tracking shares of VYNE Therapeutics Inc. (VYNE) belongs to Healthcare sector and Biotechnology industry. VYNE Inc. has a total market value of 440.80M at the time of writing – representing $167.74M outstanding shares. Turning to other widely-considered trading data, this company’s half yearly performance is observed at 60.98%.

VYNE Performance Levels

Looking performance record on shares of VYNE Therapeutics Inc. (VYNE) we observed that the stock has seen a move -51.82% over the last 52-week trading period. The stock generated performance of 37.50% tracking last 3 months. Investors will be anxiously watching to see if things will turn around and the stock will start gaining or losing momentum over the next few months. If we look back year-to-date, the stock has performed 67.09%. Shares are at 58.08% over the previous week and 49.15% over the past month.

Analyst Views: Fluctuating the focus to what the Wall Street analysts are projecting, we can see that the current consensus target price on shares is $0. Analysts often put in a lot of work to study stocks that they cover. Wall Street analysts have a consensus recommendation of 2.00on this stock. This number falls on a one to five scale where a 1 would be considered a strong buy and 5 means a strong sell, 2 shows Buy, 3 Hold, 4 reveals Sell recommendation.

Volatility Insights

Watching some historical volatility numbers on shares of VYNE Therapeutics Inc. (VYNE) we can see that the 30 days volatility is presently 6.18%. The 7 days volatility is 10.75%. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

The company has a beta of 0. 1.00 indicates that its price is correlated with the market. Less than 1.00 shows less volatility than the market. Beta greater than 1.00 indicates that the security’s price is theoretically more volatile than the market.

The Average True Range (ATR) value reported at 0.16. The average true range (ATR) is a technical analysis indicator that measures volatility by decomposing the entire range of an asset price for that period. A stock experiencing a high level of volatility has a higher ATR, and a low volatility stock has a lower ATR. The ATR may be used by market technicians to enter and exit trades, and it is a useful tool to add to a trading system. It was created to allow traders to more accurately measure the daily volatility of an asset by using simple calculations. The indicator does not indicate the price direction; rather it is used primarily to measure volatility caused by gaps and limit up or down moves. The ATR is fairly simple to calculate and only needs historical price data.

Technical Considerations

VYNE Therapeutics Inc. (VYNE) stock positioned 51.91% distance from the 200-day MA and stock price situated 55.17% away from the 50-day MA while located 56.31% off of the 20-day MA.

RSI value sited with reading of 54.55. Relative Strength Index (RSI) is an extremely useful and popular momentum oscillator. The RSI compares the magnitude of a stock’s recent gains to the magnitude of its recent losses and turns that information into a number that ranges from 0 to 100. It takes a single parameter, the number of time periods to use in the calculation. In his book, Wilder recommends using 14 periods.

Observing the Technical Indicators:

VYNE Therapeutics Inc. institutional ownership is held at 51.10% while insider ownership was 1.60%. As of now, VYNE has a P/S, P/E and P/B values of 26.40, 0 and 8.80 respectively. Its P/Cash is valued at 6.04. The Company’s net profit margin for the 12 months at 0. Comparatively, the gazes have a Gross margin 94.90%.

Profitability ratios:

Looking into the profitability ratios of VYNE stock, an investor will find its ROE, ROA, ROI standing at -487.90%, -211.50% and 0, respectively.

Earnings per Share Details of VYNE Therapeutics Inc.

The EPS of VYNE is strolling at -3.19, measuring its EPS growth this year at -30.30%. As a result, the company has an EPS growth of 0 for the approaching year.

Given the importance of identifying companies that will ensure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.

The payout ratio shows the proportion of earnings paid out as dividends to shareholders, typically expressed as a percentage of the company’s earnings. The payout ratio can also be expressed as dividends paid out as a proportion of cash flow. The payout ratio is also known as the dividend payout ratio. The Company’s payout ratio was 0 and Price to free cash flow remained $0.

Reynolds Smith

About Reynolds Smith

Myself Reynolds Smith and I am energetic about business and Healthcare & Biotech news with more than 11 years in the industry, beginning my venture as an author and later on climbing my way up into senior positions. I am the main stimulus behind Alphafinews.com started off with a dream to expand the organization’s reach out on a global scale. My writing style is diversifying, I write on a variety of topics but my personal favorite is lifestyle and business. I love communicating myself through artistic and innovative means such as writing, and painting. When I’m not doing any specific field related work, I enjoy spending some time with my dog, playing hockey or meeting my friends and family members. I never give up. I like French fries and Belgian waffles. I am an editor and contributor of the Health segment. I undergo critical analysis of corporations and extract the most significant information for our rich investor network.

View all posts by Reynolds Smith →